FDA Rejection of Replimune's Skin Cancer Therapy Sparks Investor Concerns
TL;DR
The FDA rejected Replimune's skin cancer therapy RP1 due to insufficient evidence of effectiveness and issues with clinical trial data, reflecting a tougher regulatory stance on new drug approvals.
- Replimune skin cancer therapy rejected by FDA, a sign of regulators’ hardened stance statnews.com
- Replimune's shares crater as FDA rejects melanoma drug Fierce Biotech
- FDA Rejects Replimune’s Skin Cancer Treatment, Shares Sink Yahoo Finance
- FDA rejects Replimune's oncolytic virus therapy, citing trial design and follow-up study Endpoints News
- Rosen Law Firm Encourages Replimune Group, Inc. Investors to Inquire About Securities Class Action Investigation – REPL Business Wire
Want the full story? Read the original reporting
Read on statnews.com